UnknownPhase 4NCT01111591

Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Seoul National University Hospital
Principal Investigator
Ho-Seong Han, Professor
General surgery department
Intervention
Cox2 inhibitor (Celecoxib)(drug)
Enrollment
220 enrolled
Eligibility
19-70 years · All sexes
Timeline
2008 – 2017

Study locations (1)

Collaborators

Seoul National University Bundang Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01111591 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials